Program
Linagliptin
Also written as “BI 1356”, “linagliptin” and “Linagliptin/Metformin FDC”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Esophageal Neoplasms · Carcinoma, Non-Small-Cell Lung · Hypertension, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 800 open or running | phase 4since Sep 21, 2011 | Mar 31, 2006 | none ahead |
| Dong Wha Pharmaceutical | 30 open or running | phase 1since Aug 6, 2014 | Aug 6, 2014 | none ahead |
| Profil Institut für Stoffwechselforschung | 20 open or running | phase 4since Jul 11, 2013 | Jul 11, 2013 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Aug 3, 2016 | Aug 3, 2016 | none ahead |
| ikfe-CRO | 10 open or running | phase 3since Feb 11, 2015 | Feb 11, 2015 | none ahead |
| Marcus Borchert | 10 open or running | phase 4since Feb 21, 2012 | Feb 21, 2012 | none ahead |
| Nabiqasim Industries (Pvt) | 11 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
Also a collaborator on its studies: Halozyme Therapeutics, biolinerx-ltd, Eli Lilly, eva-pharma, ikfe-gmbh and mlm-medical-labs-gmbh.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 42 studies since Sep 21, 2011.
- Aug 19, 20143 phase 1 studies in HealthyBoehringer Ingelheim · NCT02221414, NCT02221401, NCT02220647
- Sep 15, 2014Phase 4 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT02240680 · 302 enrolled · United States, Australia, Belgium and more
- Dec 11, 2014Phase 4 study in Diabetes Mellitus, Type 2Profil Institut für Stoffwechselforschung · NCT02401880 · 89 enrolled · Germany
- Feb 11, 2015ikfe-CRO's first study: phase 3 study in HypertensionNew to ikfe-CROikfe-CRO · NCT02376075 · 43 enrolled · Germany
- May 21, 2015Phase 3 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT02453555 · 275 enrolled · Japan
- Apr 29, 2016Phase 1 study in HealthyBoehringer Ingelheim · NCT02758171 · 56 enrolled · Germany
- Jun 24, 20162 phase 1 studies in HealthyBoehringer Ingelheim · NCT02815644, NCT02821910
- Aug 3, 2016Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT02857946 · 24 enrolled · Egypt
- Aug 30, 2016Phase 3 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT02897349 · 206 enrolled · China
- Aug 22, 2017Phase 1 study in HealthyBoehringer Ingelheim · NCT03259490 · 30 enrolled · Germany
- Feb 6, 2018Phase 3 study in Diabetes Mellitus, Type 2Boehringer Ingelheim · NCT03429543 · 175 enrolled · United States, Argentina, Brazil and more
- Aug 9, 2018Phase 1 study in HealthyBoehringer Ingelheim · NCT03629054 · 30 enrolled · Germany
- Apr 6, 20232 phase 1 studies in Healthy SubjectsDong Wha Pharmaceutical · NCT05874180, NCT05874167
- Feb 19, 2025Nabiqasim Industries (Pvt)'s first study: phase 4 study in Diabetes MellitusNew to Nabiqasim Industries (Pvt)Nabiqasim Industries (Pvt) · NCT06862739 · 800 planned · Pakistan
TargetBeta
“A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sitagliptinrule | Merck | phase 4 | 123 |
| gemigliptinrule | LG Chem | phase 4 | 30 |
| anagliptinrule | JW Pharmaceutical | phase 4 | 6 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
The newest 60 of 89 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06862739Diabetes Mellitus · Pakistan | 4 | Recruiting | Nabiqasim Industries (Pvt) | Apr 30, 2026 | 800 |
| NCT05874180Healthy Subjects · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Feb 1, 2023 | 31 |
| NCT05874167Healthy Subjects · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Oct 11, 2022 | 50 |
| NCT03629054Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 5, 2018 | 30 |
| NCT03429543Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Completed | Boehringer Ingelheim | Oct 19, 2022 | 175 |
| NCT03259490Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Nov 13, 2017 | 30 |
| NCT02897349Diabetes Mellitus, Type 2 · China | 3 | Completed | Boehringer Ingelheim | Jan 11, 2019 | 206 |
| NCT02857946Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Mar 2016 | 24 |
| NCT02821910Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Oct 1, 2016 | 50 |
| NCT02815644Healthy · Japan | 1 | Completed | Boehringer Ingelheim | Oct 5, 2016 | 22 |
| NCT02758171Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 29, 2016 | 56 |
| NCT02453555Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Boehringer Ingelheim | Aug 26, 2016 | 275 |
| NCT02376075Hypertension · Germany | 3 | Completed | ikfe-CRO | Sep 2014 | 43 |
| NCT02401880Diabetes Mellitus, Type 2 · Germany | 4 | Completed | Profil Institut für Stoffwechselforschung | Dec 2015 | 89 |
| NCT02240680Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more | 4 | Completed | Boehringer Ingelheim | Apr 18, 2017 | 302 |
| NCT02221414Healthy | 1 | Completed | Boehringer Ingelheim | Mar 2010 | 95 |
| NCT02221401Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2010 | 96 |
| NCT02220647Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2010 | 96 |
| NCT02212782Healthy · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Nov 2014 | 12 |
| NCT02191228Renal Insufficiency | 1 | Completed | Boehringer Ingelheim | Feb 2010 | 51 |
| NCT02183636Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2009 | 39 |
| NCT02183623Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2005 | 20 |
| NCT02183610Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2006 | 12 |
| NCT02183584Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2009 | 16 |
| NCT02183532Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2009 | 12 |
| NCT02183506Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2005 | 16 |
| NCT02183493Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2008 | 32 |
| NCT02183480Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2009 | 12 |
| NCT02183467Healthy | 1 | Completed | Boehringer Ingelheim | Jun 2008 | 44 |
| NCT02183428Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2008 | 20 |
| NCT02183415Diabetes Mellitus, Type 2 | 1 | Completed | Boehringer Ingelheim | Jan 2006 | 77 |
| NCT02183402Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2008 | 20 |
| NCT02183389Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2008 | 18 |
| NCT02183376Hepatic Insufficiency | 1 | Completed | Boehringer Ingelheim | Mar 2009 | 33 |
| NCT02183363Healthy | 1 | Completed | Boehringer Ingelheim | May 2007 | 24 |
| NCT02183350Diabetes Mellitus, Type 2 | 1 | Completed | Boehringer Ingelheim | Aug 2005 | 47 |
| NCT02183337Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2007 | 20 |
| NCT02183324Diabetes Mellitus, Type 2 | 2 | Completed | Boehringer Ingelheim | Jun 2007 | 72 |
| NCT02183311Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2006 | 56 |
| NCT02183298Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2006 | 36 |
| NCT02180503Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2005 | 24 |
| NCT02175394Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2008 | 18 |
| NCT02173665Healthy | 1 | Completed | Boehringer Ingelheim | Dec 2004 | 64 |
| NCT02173652Healthy | 1 | Completed | Boehringer Ingelheim | Apr 2008 | 16 |
| NCT02173639Healthy | 1 | Completed | Boehringer Ingelheim | Jun 2009 | 20 |
| NCT02121509Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2014 | 74 |
| NCT02084082Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2014 | 68 |
| NCT02084056Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2014 | 74 |
| NCT01947153Healthy · Russian Federation | 1 | Completed | Boehringer Ingelheim | Jan 2014 | 36 |
| NCT01903070Diabetes Mellitus · Germany | 4 | Completed | Profil Institut für Stoffwechselforschung | Apr 2016 | 99 |
| NCT01897532Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 4 | Completed | Boehringer Ingelheim | Jan 18, 2018 | 6,991 |
| NCT01845077Healthy · United States | 1 | Completed | Boehringer Ingelheim | Aug 2013 | 72 |
| NCT01792518Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more | 3 | Completed | Boehringer Ingelheim | Nov 2015 | 360 |
| NCT01708902Diabetes Mellitus, Type 2 · China, Malaysia, Philippines and more | 3 | Completed | Boehringer Ingelheim | Apr 2014 | 876 |
| NCT01703286Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Boehringer Ingelheim | Jan 2014 | 42 |
| NCT01581931Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jun 2012 | 32 |
| NCT01540487Healthy · China | 1 | Completed | Boehringer Ingelheim | Jun 2012 | 48 |
| NCT01547104Diabetes Mellitus, Type 2 · Germany | 4 | UNKNOWN | Marcus Borchert | Oct 2012 | 40 |
| NCT01512979Diabetes Mellitus, Type 2 · United States, Canada, India and more | 4 | Completed | Boehringer Ingelheim | Apr 2013 | 316 |
| NCT01438814Diabetes Mellitus, Type 2 · Bangladesh, Belgium, Canada and more | 4 | Completed | Boehringer Ingelheim | Mar 2013 | 689 |
How it is read
Names in the registry
- “Linagliptin”, 35 entries
- “BI 1356”, 14 entries
- “linagliptin”, 10 entries
- “Linagliptin/Metformin FDC”, 4 entries
- “BI 1356 BS”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 46 studies
- Diabetes Mellitus, 2 studies
- Esophageal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.